24 March 2017

Director/PDMR Dealing

Collagen Solutions plc (AIM: COS), the developer and manufacturer of medical grade collagen components for use in regenerative medicine, medical devices and in-vitro diagnostics, announces that it was notified yesterday that David Evans, Chairman of the Company, has purchased 434,950 ordinary shares in the Company ("Ordinary Shares") at 5.0 pence per Ordinary Share.

Following the transaction, David Evans' total beneficial holding in the Company has increased to 35,809,117 Ordinary Shares representing 11.32 per cent. of the issued ordinary share capital of the Company.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1 Details of the person discharging managerial responsibilities / person closely associated
a) Name David Evans
2 Reason for the notification
a) Position/status Chairman
b) Initial notification / Amendment Initial
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name Collagen Solutions plc
b) LEI N/A
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument
Identification code
Ordinary shares of 1p each
ISIN: GB00B94T6Y14
b) Nature of the transaction Purchase of shares
c) Price(s) and volume(s)
Price(s) Volume(s)
5p per share 434,950
d) Aggregated information
- Aggregated volume
- Price

N/A - single transaction
e) Date of the transaction 23 March 2017
f) Place of the transaction London Stock Exchange

 

About Collagen Solutions:  

Collagen Solutions Plc is a global supplier, developer, and manufacturer of medical grade collagen, tissues, and related medical devices and components for use in regenerative medicine, medical devices and in-vitro diagnostics and research. The Company is also expanding its range of biomaterials-based finished medical devices based on its internal and acquired intellectual property for commercialisation with partners via licensing and distribution arrangements, including ChondroMimetic, an osteochondral scaffold for repairing cartilage defects in the knee. The Company's products are used in a wide variety of applications including orthopaedics, cardiovascular, dental, plastic surgery, wound healing, neurology and urology.

For additional information on Collagen Solutions, please visit: www.collagensolutions.com

Enquiries: 

Collagen Solutions Plc Contact via Walbrook
Jamal Rushdy, Chief Executive Officer
Gill Black, Chief Financial Officer
 
   
Cenkos Securities plc (Nominated Adviser and Broker)
Stephen Keys
Steve Cox 
Callum Davidson
Tel: 0207 397 8900
   
Walbrook PR
Mike Wort
Anna Dunphy
Tel: 020 7933 8780 or collagen@walbrookpr.com
Mob: 07900 608 002
Mob: 07876 741 001